News

Continued Roll-out of Innovative Molecular Laboratory Developed Tests from Sequenom Center for Molecular MedicineSAN DIEGO, Feb 16, 2010 /PRNewswire via COMTEX/ -- Sequenom, Inc. (Nasdaq: SQNM) today announced the launch of the SensiGene(TM) Fetal(XY) (Fetal Sex Determination) test by Sequenom's CAP accredited and CLIA-certified laboratory, Sequenom Center for Molecular Medicine (Sequenom CMM). This is the company's second laboratory developed test powered by its SEQureDx(TM) technology. (Logo: http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO) The benefits of the SensiGene Fetal(XY) Fetal Sex Determination test include: Noninvasive and safe. The test requires only a s...

SAN DIEGO, Feb 09, 2010 /PRNewswire via COMTEX/ -- Sequenom, Inc. (Nasdaq: SQNM), today announced an exclusive worldwide licensing agreement with Optherion, Inc. Under the agreement, Sequenom's CAP accredited and CLIA-certified laboratory, Sequenom Center for Molecular Medicine (Sequenom CMM), obtained the rights to develop and commercialize diagnostic tests to predict genetic predisposition to late stage age-related macular degeneration (AMD). (Logo: http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO) The license agreement covers extensive intellectual property rights for the most significant AMD-related genetic variants that have been confirmed in multiple clinical studies around t...

First Commercial Test using SEQureDx Technology for Determining Rhesus D IncompatibilitySAN DIEGO, Feb 04, 2010 /PRNewswire via COMTEX/ -- Sequenom, Inc. (Nasdaq: SQNM) today announced the launch of the SensiGene(TM) Fetal RHD Genotyping test by Sequenom's CAP accredited and CLIA-certified laboratory, Sequenom Center for Molecular Medicine (Sequenom CMM). This is the company's first laboratory developed test powered by its SEQureDx(TM) technology. (Logo: http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO) In the United States, there are approximately 528,000 pregnancies in Rhesus D (RhD) negative women every year, and almost all of these women could benefit from an assessment of the ...

SAN DIEGO, Sept. 17 /PRNewswire-FirstCall/ -- SEQUENOM, Inc. (Nasdaq: SQNM) today announced that the company's first laboratory developed test, the SensiGene(TM) Cystic Fibrosis (CF) Carrier Screening test, has been launched. This test is available exclusively through the Sequenom Center for Molecular Medicine, a next-generation CLIA (Clinical Laboratory Improvement Amendments, 1988) molecular diagnostic laboratory and a wholly-owned subsidiary of Sequenom, Inc. (Logo: http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO) The SensiGene CF Carrier Screening Test -- This innovative test screens for 103 mutations and five variants, including the 23 mutation...

SADDLE RIVER, N.J. & SAN DIEGO, Mar 03, 2009 (BUSINESS WIRE) -- PDI, Inc. (NASDAQ:PDII), and Sequenom Center for Molecular Medicine, LLC (SCMM), a wholly owned subsidiary of Sequenom, Inc. (NASDAQ:SQNM) announced today that PDI has been selected to provide the sales infrastructure to launch and commercialize SCMM's noninvasive prenatal genetic screening tests based on its SEQureDx(TM) technology. Under the direction of SCMM management, PDI will support the commercialization of SCMM's fetal Rhesus D genotyping test from a maternal blood sample. This test will reduce the risk to the mother and fetus by providing clinicians early and accu...

Collaboration with Leading Maternal-Fetal Medicine Physician Group Signifies Further Step Toward Commercializing Trisomy 21 Test SAN DIEGO--(BUSINESS WIRE)-- Sequenom, Inc. (NASDAQ:SQNM), today announced a collaboration with Obstetrix Medical Group, to provide the Sequenom Center for Molecular Medicine (SCMM) with samples for a study to further evaluate its novel, noninvasive prenatal test to assess Down syndrome (Trisomy 21) based on its circulating cell-free fetal (ccff) nucleic acid SEQureDx™ technology. Obstetrix is a national physician group practice of maternal-fetal medicine specialists that is affiliated with Pediatrix Medi...